title: Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study.
abstract: OBJECTIVE
  The objective of this study was to evaluate whether hydroxychloroquine (HCQ) therapy effects subjective and/or objective complaints and salivary flow rates of patients with primary Sjögren's syndrome (PSS).
  
  
  METHODS
  Thirty women recently diagnosed with PSS, scheduled for HCQ treatment (400 mg daily), participated and were clinically examined before initiation of 30 weeks of HCQ treatment. During baseline evaluation, both the objective and/or subjective oral findings were recorded. Unstimulated (uSFR) and stimulated salivary flow rates (sSFR) were determined. After initiation of HCQ treatment, study parameters were assessed at 6, 12, 18, 24, and 30 weeks. Each patient served as her own control; measurements of the baseline and control times were analyzed by ANOVA.
  
  
  RESULTS
  uSFR values increased significantly with HCQ treatment, but sSFR values, objective and/or subjective complaints did not change considerably.
  
  
  CONCLUSIONS
  A positive impact of 30 weeks of HCQ treatment only on uSFRs of SS patients was revealed.
authors.affiliation: Department of Oral Diagnosis and Radiology, Faculty of Dentistry, Ege University, Bornova/Izmir, Turkey.
authors.forename: Hulya
authors.initials: H
authors.lastname: Cankaya
authors.forename: Esin
authors.initials: E
authors.lastname: Alpöz
authors.forename: Gonca
authors.initials: G
authors.lastname: Karabulut
authors.forename: Pelin
authors.initials: P
authors.lastname: Güneri
authors.forename: Hayal
authors.initials: H
authors.lastname: Boyacioglu
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Kabasakal
mesh_terms: D000328:Adult; D000368:Aged; D002054:Burning Mouth Syndrome / Q000188:drug therapy / Q000523:psychology; D002613:Cheilitis / Q000188:drug therapy / Q000523:psychology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003679:Deglutition / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D008409:Mastication / Q000502:physiology; D008875:Middle Aged; D017060:Patient Satisfaction; D012463:Saliva / Q000187:drug effects* / Q000378:metabolism; D012636:Secretory Rate / Q000187:drug effects; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000523:psychology; D016896:Treatment Outcome; D014987:Xerostomia / Q000188:drug therapy / Q000523:psychology
chemical_list: D002800:Cholinesterase Inhibitors; D004791:Enzyme Inhibitors; D006886:Hydroxychloroquine